All

Citalid Secures U.S. Patent for Automated Cyberattack Simulation Powering Its CRQ Platform
17 March 2026

Citalid Secures U.S. Patent for Automated Cyberattack Simulation Powering Its CRQ Platform

Citalid, the leading cyber risk quantification (CRQ) tech provider in Europe, today announced the grant of U.S. Patent No. 12,542,803 B2 for a proprietary automated cyberattack...

Read more
IDnow adopts AI‑powered contact center platform to handle growing IDV volumes
9 March 2026

IDnow adopts AI‑powered contact center platform to handle growing IDV volumes

Identity verification provider IDnow has selected Bright Pattern’s AI‑driven contact center platform to support more than one million video‑based identifications per...

Read more
TransferGo enters new stage of growth: Bank of Lithuania expands company’s EMI license
19 February 2026

TransferGo enters new stage of growth: Bank of Lithuania expands company’s EMI license

The Bank of Lithuania has supplemented the electronic money institution (EMI) license for the fintech company Ltd TransferGo Lithuania. This enhancement enables the company to...

Read more
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Read more
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10 February 2026

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close...

Read more
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
29 January 2026

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of...

Read more
ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate
21 January 2026

ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate

ErVimmune, a biotechnology company developing next-generation therapeutic vaccines targeting new families of ‘unconventional’ tumor antigens derived from human endogenous...

Read more
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
20 January 2026

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in...

Read more